IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
High Dose Nimodipine Treatment Adjunct - 1
This study has been completed.
Sponsor:
National Institute on Drug Abuse (NIDA)
Collaborator:
Washington D.C. Veterans Affairs Medical Center
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000332
First received: September 20, 1999
Last updated: February 23, 2017
Last verified: December 2002
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if nimodipine is more effective than placebo in reducing stimulated craving for cocaine in cocaine dependent individuals denied access to cocaine in inpatient unit.
| Condition | Intervention | Phase |
|---|---|---|
| Cocaine-Related Disorders | Drug: Nimodipine | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Official Title: | High Dose Nimodipine Pharmacotherapy Adjunct |
Resource links provided by NLM:
Further study details as provided by National Institute on Drug Abuse (NIDA):
Primary Outcome Measures:
- Stimulated and non-stimulated craving
- Stimulated and non-stimulated withdrawal
- Anxiety, depression
- Heart rate
| Estimated Enrollment: | 0 |
| Actual Study Start Date: | May 1998 |
| Study Completion Date: | April 2000 |
| Primary Completion Date: | January 2000 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 22 Years to 45 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Please contact site for information.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000332
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000332
Locations
| United States, District of Columbia | |
| Washington DC VA | |
| Washington, District of Columbia, United States, 20422 | |
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Washington D.C. Veterans Affairs Medical Center
Investigators
| Principal Investigator: | Steven Deutsch, M.D. | Washington D.C. Veterans Affairs Medical Center |
More Information
| ClinicalTrials.gov Identifier: | NCT00000332 History of Changes |
| Other Study ID Numbers: |
NIDA-3-0009-1 Y01-3-0009-1 |
| Study First Received: | September 20, 1999 |
| Last Updated: | February 23, 2017 |
| Studies a U.S. FDA-regulated Drug Product: | Yes | |
| Studies a U.S. FDA-regulated Device Product: | No | |
Additional relevant MeSH terms:
|
Cocaine-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Nimodipine |
Antihypertensive Agents Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Vasodilator Agents |
ClinicalTrials.gov processed this record on June 22, 2017